Journal article
Medical Management of Gastroenteropancreatic Neuroendocrine Tumors
Surgical oncology clinics of North America, Vol.29(2), pp.293-316
04/2020
DOI: 10.1016/j.soc.2019.11.004
PMCID: PMC7700751
PMID: 32151362
Abstract
The increased incidence and prevalence of neuroendocrine tumors (NETs) over the past few decades has been accompanied by an improvement in overall survival. There are differences in the management of small bowel NETs versus pNETs. The management of all patients with NETs must be individualized based on patient characteristics as well tumor-related factors. This article reviews the role of somatostatin analogues, historical results with chemotherapy in gastroenteropancreatic NETs (GEPNETs), and more recent evidence for the use of cytotoxic chemotherapy in GEPNETs. The article also discusses molecular targeted therapies approved for use in GEPNETs and some ongoing clinical trials.
Details
- Title: Subtitle
- Medical Management of Gastroenteropancreatic Neuroendocrine Tumors
- Creators
- Chandrikha Chandrasekharan - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Surgical oncology clinics of North America, Vol.29(2), pp.293-316
- DOI
- 10.1016/j.soc.2019.11.004
- PMID
- 32151362
- PMCID
- PMC7700751
- NLM abbreviation
- Surg Oncol Clin N Am
- ISSN
- 1055-3207
- eISSN
- 1558-5042
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 04/2020
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984360045802771
Metrics
9 Record Views